Teva Pharmaceutical Industries (TEVJF) Change in Accured Expenses (2025 - 2026)

Teva Pharmaceutical Industries (TEVJF) recorded quarterly Change in Accured Expenses of -$144.0 million in Q1 2026, down 251.22% on a QoQ basis from -$41.0 million in Q1 2025, and down 251.22% year-over-year from $95.2 million in Q1 2025.

Teva Pharmaceutical Industries (TEVJF) Change in Accured Expenses (2025 - 2026) Analysis & Trends

Teva Pharmaceutical Industries has disclosed Change in Accured Expenses across 2 years of filings, most recently posting -$144.0 million for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn -144.00 Mn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn -234.00 Mn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn -12.70 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn -
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn -14.30 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn -
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn 4.89 Mn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn 10.02 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 23.00 Mn
10 Teva Pharmaceutical Industries - - 1.97 Bn -144.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -144.00 Mn
Mar 31, 2026 -144.00 Mn
Mar 31, 2025 -41.00 Mn
Mar 31, 2025 -41.00 Mn